These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 23460149)
1. Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes. Sterman DH Chest; 2013 Mar; 143(3):597-600. PubMed ID: 23460149 [No Abstract] [Full Text] [Related]
2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
3. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140 [TBL] [Abstract][Full Text] [Related]
9. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib. Pennell NA; Yin L; Keshtgarpour M; Ma PC J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608 [No Abstract] [Full Text] [Related]
10. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Sequist LV; Haber DA; Lynch TJ Clin Cancer Res; 2005 Aug; 11(16):5668-70. PubMed ID: 16115901 [No Abstract] [Full Text] [Related]
11. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? Gandara DR; Gumerlock PH J Clin Oncol; 2005 Sep; 23(25):5856-8. PubMed ID: 16043825 [No Abstract] [Full Text] [Related]
12. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271 [TBL] [Abstract][Full Text] [Related]
13. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. Takeda M; Okamoto I; Fujita Y; Arao T; Ito H; Fukuoka M; Nishio K; Nakagawa K J Thorac Oncol; 2010 Mar; 5(3):399-400. PubMed ID: 20186026 [TBL] [Abstract][Full Text] [Related]
14. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. Pietanza MC; Lynch TJ; Lara PN; Cho J; Yanagihara RH; Vrindavanam N; Chowhan NM; Gadgeel SM; Pennell NA; Funke R; Mitchell B; Wakelee HA; Miller VA J Thorac Oncol; 2012 Jan; 7(1):219-26. PubMed ID: 22011666 [TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073 [TBL] [Abstract][Full Text] [Related]
16. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502 [TBL] [Abstract][Full Text] [Related]
17. Erlotinib in lung cancer. Takano T; Ohe Y N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240472 [No Abstract] [Full Text] [Related]
18. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M; J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258 [TBL] [Abstract][Full Text] [Related]
19. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations. Lee CN; Chen HY; Liu HE J Clin Oncol; 2010 Mar; 28(7):e111-2. PubMed ID: 20008635 [No Abstract] [Full Text] [Related]
20. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]